Form 4: Beam Therapeutics CMO Granted 88,500 Stock Options

Beam Therapeutics' Chief Medical Officer, Amy Simon, was granted 88,500 stock options with an exercise price of $27.62, vesting over four years.

Summary

• Amy Simon, Chief Medical Officer of Beam Therapeutics Inc. (BEAM), was granted 88,500 stock options.
• The stock options have an exercise price of $27.62 per share.
• The options were granted on January 31, 2026, and expire on January 31, 2036.
• Vesting occurs in equal monthly installments over 48 months, contingent on Ms. Simon's continued service with the company.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting standard executive compensation practices that align management incentives with shareholder interests and support executive retention.

Positives

• The grant of stock options aligns the Chief Medical Officer's financial interests with the long-term performance of Beam Therapeutics, incentivizing sustained commitment and value creation.
• This compensation structure is a common practice for retaining key executive talent in the biotechnology sector.

Future Outlook

The 48-month vesting schedule for the stock options indicates an expectation of continued service from the Chief Medical Officer, reinforcing stability in key leadership roles over the medium term.

Industry Context

StockSavvy.ai notes that stock option grants are a standard component of executive compensation packages in the biotechnology industry, designed to attract, retain, and motivate senior leadership by linking their personal wealth to the company's stock performance. This practice is particularly prevalent in growth-oriented sectors like biotech, where long-term value creation is paramount.

Comparison to Industry Standards

• Stock option grants with multi-year vesting schedules are a common and competitive compensation tool for Chief Medical Officers in the biotech industry.
• The size of the grant (88,500 options) and the four-year vesting period are typical for a senior executive at a clinical-stage biotechnology company like Beam Therapeutics, comparable to similar grants observed at peers such as CRISPR Therapeutics or Editas Medicine for equivalent roles.

Related Party Transactions

• The grant of stock options to Amy Simon, the Chief Medical Officer, constitutes a related party transaction as she is an officer of Beam Therapeutics Inc.

Stakeholder Impact

• Shareholders: The grant aims to align the Chief Medical Officer's interests with shareholder value creation, potentially leading to better long-term performance.
• Employees (specifically the CMO): Provides a significant equity incentive, enhancing personal wealth potential tied to company success and encouraging retention.

Next Steps

• The granted stock options will vest in equal monthly installments over the next 48 months, subject to the Chief Medical Officer's continued employment.

Key Dates

Keywords

Beam Therapeutics, BEAM, stock option, executive compensation, Form 4, Amy Simon, Chief Medical Officer, equity grant